ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation (BTL)
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dose of bupivacaine that provides effective
pain management in 90% (ED90) of patients undergoing bilateral tubal ligation. This will
guide anesthesiologists on the most effective dose to minimize intraoperative pain during
this procedure. The goal is to make women as comfortable as possible when they undergo this
procedure while also minimizing the amount of time they are required to remain in the
hospital afterwards for monitoring.